incretin


Also found in: Dictionary, Wikipedia.
Related to incretin: Sitagliptin

in·cre·tin

(in-krē'tin),
Generic term for all insulinotropic substances originating in the gastrointestinal tract that are released into the circulation by meals containing glucose. One is glucose-dependent insulinotropic polypeptide, which is released into the circulation from crypt cells in the proximal duodenum and jejunum after meals containing glucose or long-chain fatty acids. Another is proglucagon-derived polypeptide, cleavage product of glucagon, which is further processed into glucagonlike peptide-1 and then to glucagonlike insulinotropic peptide.

incretin

(ĭn-krēt′n)
n.
Any of several gastrointestinal hormones that bring about the release of insulin from the pancreas after carbohydrate ingestion and are essential in maintaining normal levels of glucose in the blood.

in·cre·tin

(in-krē'tin)
Generic term for all insulinotropic substances originating in the gastrointestinal tract that are released into the circulation by meals containing glucose. One is the glucose-dependent insulinotropic polypeptide, which is released into the circulation from crypt cells in the proximal duodenum and jejunum after meals containing glucose or long-chain fatty acids. Another is proglucagon-derived polypeptide, a cleavage product of glucagon, which is further processed into glucagonlike peptide-1 and then to glucagonlike insulinotropic peptide.
Compare: bioregulator

in·cre·tin

(in-krē'tin)
Generic term for all insulinotropic substances originating in the gastrointestinal tract.
References in periodicals archive ?
A 2013 study of brain-dead organ donors did find a 40% increased pancreatic mass in diabetes patients treated with incretin therapy, compared to those who didn't get it and to controls.
Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that is commonly used in the treatment of type II diabetes mellitus (DM) for its effect on the incretin system (1).
Incretin mimetics are long-acting analogs of the gastric hormones called incretins, such as glucagon-like peptide-1 (GLP-1), which stimulate insulin release.
a) inhibiting the activity of the DPP-IV enzyme to prolong the effects of incretin
The most important incretin in glucose regulation is the glucagon-like peptide (GLP-1).
Medications that Restore Incretin Action (DPP-4 Inhibitors)
Already, a weekly incretin injection is close to Food & Drug Administration approval.
Glucose-dependent insulinotropic peptide (GIP) was the first and glucagon-like peptide 1 (GLP-1) the second, and final, incretin to be characterised.
Specially structure and function deterioration almost in 50% of [beta]-cell mass is observed in type 2 diabetes mellitus, but also incretin metabolism is abnormal because there is an evident decrease on incretin effect [5, 6], that is the reason of the reduction in nutrient-mediated secretion of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) [7], this effect leads to an inappropriately elevated glucagon concentrations that results in hyperglycemia [3, 4].
Exenatide is the first and only approved incretin mimetic, a class of drugs for
Pseudin could join a new class of medicines called incretin mimetics which mimic natural substances.